^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    melphalan

    i
    Other names: L-PAM, L-sarcolysin, phenylalanine mustard
    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    8d
    NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)
    P2, N=42, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2026 --> Mar 2026
    Trial completion • Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • dexrazoxane
    8d
    Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders (clinicaltrials.gov)
    P2, N=260, Active, not recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Mar 2027
    Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • etoposide IV • sirolimus • melphalan • fludarabine IV • busulfan
    13d
    High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    cytarabine • etoposide IV • carmustine • melphalan • Neulasta (pegfilgrastim) • vadacabtagene leraleucel (JCAR015)
    14d
    Improving public cancer care by implementing precision medicine in Norway (2023-507894-16-00)
    P1/2, N=1000, Recruiting, Oslo University Hospital HF | N=6000 --> 1000
    Enrollment change
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • Rozlytrek (entrectinib) • imatinib • Alecensa (alectinib) • Cotellic (cobimetinib) • bortezomib • Piqray (alpelisib) • Zejula (niraparib) • Retevmo (selpercatinib) • Zykadia (ceritinib) • fulvestrant • Jemperli (dostarlimab-gxly) • Pemazyre (pemigatinib) • Tepmetko (tepotinib) • Tabrecta (capmatinib) • Erivedge (vismodegib) • melphalan • dactinomycin • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • hydroxyurea
    15d
    Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial (clinicaltrials.gov)
    P2, N=74, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    lenalidomide • carfilzomib • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Tecvayli (teclistamab-cqyv) • Hemady (dexamethasone tablets) • plerixafor
    19d
    TT4B: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma (clinicaltrials.gov)
    P3, N=382, Active, not recruiting, University of Arkansas | Trial completion date: Sep 2027 --> Sep 2028 | Trial primary completion date: Sep 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 deletion
    |
    cisplatin • bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • thalidomide • melphalan
    19d
    UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, University of Arkansas | Trial primary completion date: Oct 2026 --> Oct 2027 | Trial completion date: Oct 2027 --> Oct 2028
    Trial completion date • Trial primary completion date
    |
    SDC1 (Syndecan 1)
    |
    cisplatin • bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • thalidomide • melphalan
    21d
    FT-RIC-HAPLO: FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML (clinicaltrials.gov)
    P2, N=77, Not yet recruiting, Institut Paoli-Calmettes
    New P2 trial
    |
    cyclophosphamide • melphalan • fludarabine IV • Grafapex (treosulfan)
    23d
    Superior long-term survival with acceptable safety of ATG/G-CSF-based haplo-HSCT with intensified BU+MEL/TT conditioning in CR Pediatric Non-DS-AMKL. (PubMed, Front Oncol)
    Allo-HSCT in first complete remission (CR1) is recommended as the preferred strategy for improving survival, yet the benefit of BU/CY intensification with melphalan (MEL) or thiotepa (TT) remains unclear. In pediatric non-DS-AMKL, intensified conditioning (BU+MEL/TT) independently improved OS and LFS in patients transplanted in CR without increasing early NRM. Pre-transplant NR/PR status was the strongest adverse factor, markedly increasing RI and NRM, underscoring the importance of achieving remission before transplantation.
    Journal
    |
    CD34 (CD34 molecule)
    |
    melphalan • thiotepa
    24d
    Cytotoxic Profiling of 3',4',5'-Trimethoxychalcones Reveals Cell-Line-Dependent Cytotoxic Activity: An In Vitro and In Silico Study. (PubMed, Chem Biodivers)
    Most derivatives showed higher cytotoxic potency than the reference drug melphalan in the more responsive models...In the doxorubicin-resistant HL-60/DOX (multidrug-resistant promyelocytic leukemia) subline, 10 retained activity...Similar binding to human serum albumin was observed. Overall, these findings support cell-line-resolved evaluation and context-aware optimization in 3',4',5'-trimethoxychalcone-based anticancer research.
    Preclinical • Journal
    |
    ER (Estrogen receptor) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    ER positive
    |
    doxorubicin hydrochloride • melphalan
    26d
    Haplo-Cord HSCT for AML/MDS (clinicaltrials.gov)
    P=N/A, N=180, Recruiting, Fujian Medical University Union Hospital
    New trial
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    NPM1 mutation • KIT mutation
    |
    cytarabine • cyclophosphamide • melphalan • fludarabine IV • busulfan
    28d
    CAR-T+ASCT: CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors. (clinicaltrials.gov)
    P2, N=20, Recruiting, Zhejiang Cancer Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    TP53 mutation
    |
    cytarabine • Yescarta (axicabtagene ciloleucel) • carmustine • melphalan